Background. Persistent human papillomavirus (HPV) infection is the most important risk factor for cervical cancer, and understanding genotype-specific HPV persistence is essential for elucidating the natural history of HPV infections.
tract belong to the alpha-papillomavirus genus, which includes 15 species and 58 HPV genotypes. According to their clinical behavior, 15 HPV types are classified as high-risk types (HPV types 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 68, 73, and 82), 12 are classified as low-risk HPV types (HPV types 6, 11, 40, 42, 44, 54, 61, 70, 72, 81, and CP6108), whereas 3 are probable high-risk types (HPV types 26, 53, and 66) [3] . Worldwide, the 8 most common HPV types found in cervical cancer are all included either in species 7 (HPV types 18 and 45) or species 9 (HPV types 16, 31, 33, 35, 52 , and 58) [4] .
Because of their intimate link with cervical cancer, high-risk HPV infections have been studied more intensely than low-risk infections, of which only a few longitudinal studies are available [5, 6] . As part of multiple-type infections, low-risk types can be associated with cervical cancer or high-grade cervical intraepithelial neoplasia [7] , but their impact in the etiology of cervical intraepithelial neoplasia lesions is not clear [8, 9] . Of all high-risk HPV types, HPV16 has been regarded as the most persistent type [5, [10] [11] [12] . Some authors have shown that multiple-type HPV infections prolong the time of persistence of high-risk infections [13, 14] , whereas others have failed to show such an increase [10, 12, 15] . Other cofactors of high-risk HPV in cervical carcinogenesis include smoking, long-term use of oral contraceptives, high parity, number of sex partners, and exposure to other sexually transmitted diseases (eg, Chlamydia trachomatis, herpes simplex virus 2, and human immunodeficiency virus) [16, 17] .
To cast additional light on the dynamics of HPV infections in a longitudinal setting, the present study evaluated genotypespecific point prevalence and persistence of both low-risk and high-risk HPV infection during a 6-year prospective follow-up of 1300 women in the Finnish Family HPV study. Demographic data and records on risk factors of persistent infection were analyzed as potential predictors of genotype-specific persistence of high-risk HPV infections.
MATERIALS AND METHODS

Subjects.
The Finnish Family HPV Study is a prospective cohort study conducted at the Department of Obstetrics and Gynecology, Turku University Hospital, and at the Institute of Dentistry, Faculty of Medicine, University of Turku. The design of the study is shown in Figure 1 .
The subjects in this cohort include women who were recruited at a minimum of 36 weeks of pregnancy [18] and were followed up for up to 6 years after the delivery. All women are of Caucasian origin and have the same ethnic background. The Joint Commission on Ethics of Turku University and Turku University Hospital has approved the study protocol and its amendment (#2/1998 and #2/2006). Altogether, 331 mothers were recruited, of whom 304 were included in this analysis, which required a minimum of 2 follow-up visits. The main reasons for losing 27 women to follow-up were difficulties in attending the visits because of work or family reasons. The number of women examined at each follow-up visit is given in Figure 1 , which also gives the mean follow-up times.
Samples. The scrapings for HPV testing were obtained at baseline and at the 2-month, 12-month, 24-month, 36-month, and 6-year follow-up visits. Sampling was performed with a cytobrush from the mucosa of the uterine cervix (Cytobrush; MedScand) with use of a sampling media (0.05 mol/L phosphate-buffered saline with 100 mg genamycin). The samples were immediately frozen at Ϫ20ЊC and stored at Ϫ70ЊC. The scrapings from oral mucosa were collected as described elsewhere [19] , but in this study, only the baseline DNA data were used in the analyses.
Pap smears.
A routine pap smear was obtained for all women at the baseline visit and at 12, 24, and 36 months, by use of the conventional 3-sample technique with wooden spatulas and a cytobrush (Medscand), as described elsewhere [18] .
HPV DNA testing. HPV DNA was extracted from the genital scrapings with the high salt method, as described elsewhere [20] . HPV testing was performed with polymerase chain reaction (PCR) with GP05+/GP06+ primers [21] . The PCR products were hybridized with digoxigenin-labeled high-risk HPV oligoprobe cocktail (including HPV types 16, 18, 31, 33, 35, 39, 45 , 51, 52, 54, 56, and 58) to determine whether the sample was high-risk HPV positive or high-risk HPV negative [22] . To identify the HPV genotypes, the PCR products were reamplified for biotinylation with GP05+ and bioGP06+ primers for beadbased multiplex HPV genotyping.
HPV genotyping. HPV genotyping was performed with a multiplex HPV genotyping kit (Multimetrix; Progen Biotechnik GmbH) based on the method described elsewhere [23] . The following 24 low-risk and high-risk HPV genotypes can be identified: low-risk HPV types 6, 11, 42, 43, 44, and 70; and high-risk HPV types 16, 18, 26, 31, 33, 35, 39, 45 , 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82. We performed the test as described elsewhere [23] , except biotinylated PCR products of the samples were used. Also, only one-half of the volume described in the original protocol was used; however, in the final step the volume was the same as in the original protocol (100 ml). After the thermal denaturation and hybridization of the biotinylated PCR product to target HPV oligoprobes bound to the beads, the labeled hybrids were then analyzed with a Luminex LX-100 analyzer. The medium fluorescence intensity (MFI) of at least 100 beads was computed for each bead set in the sample. The cutoff value for each run and HPV type was calculated on the basis of the signal of the negative control with use of the following formula:
. Cutoff p 1.5 ϫ Background MFI + 5 If any of samples had positive results for HPV16, the protocol was repeated with the original sample with PCR using GP05+ and bioGP06+ primers, followed by our in-house bead-based HPV16 genotyping assay [23] (A. Paaso, S.-M. Kulmala, K.J.S., and S.M.S., unpublished data). This test was performed to identify those samples potentially contaminated with HPV16 during the previous testing.
Statistical analyses. All statistical analyses were performed using PASW Statistics for Windows (version 18.0.1; SPSS) and STATA/SE (version 11.0; StataCorp) software packages. Frequency tables were analyzed using the x 2 test, with the likelihood ratio (low-risk) or Fisher's exact test for categorical variables. Differences in the means of continuous variables were analyzed using nonparametric (Mann-Whitney or Kruskal-Wallis) tests for 2 and multiple independent samples, respectively.
Outcomes of HPV infection and type-specific persistence. The outcomes of the HPV infections and type-specific persistence are presented in Figure 2 . At the first level, the genotypespecific outcome of HPV infection in each woman was assessed by comparing the viral events at each follow-up visit to the baseline HPV status. Six different main outcomes were identified, as shown in Figure 2 . Of these, always negative (1) and incident HPV (2) are clear-cut outcomes. Genotype-specific persistence (3) denotes any case with у2 consecutive followup samples with positive results for the same individual genotype as a single infection or as a part of multiple-type infection. Non-genotype-specific persistence (4) includes all cases with у2 consecutive samples positive for different HPV genotypes. Fluctuation (5) is a pattern where consecutive samples are intermittently HPV positive and HPV negative with different HPV genotypes, without any 2 consecutive samples positive for the same or different viral genotype. In this primary categorization, virus clearance (5) included only the baseline HPV-positive cases that cleared the infection by the last followup visit. At the second level, patterns 2-6 were further stratified by type-specific and non-type-specific persistence. Because in many cases HPV infections in individual women fit 11 outcome pattern, a second level was defined to maximally exploit the data of the different outcome patterns for viral persistence. Accordingly, the patterns 2, 3, 4, 5, and 6 were further stratified to the 2 persistent-outcome categories (2 and 3) as follows. Among category 1 (incident infections) we selected all cases demonstrating genotype-specific and non-genotype-specific persistence of this incident infection, as defined by the same criteria as described above. This resulted in new categories 2 and 3, with 71 and 106 cases, respectively. Similarly, the original categories 3 and 4 were further stratified to genotype-specific and nongenotype-specific persistence whenever they were different or additional to these same categories in the main assessment. By definition, category 5 (fluctuation) does not include any viral persistence, but importantly, the cases which where HPV negative at the last follow-up visit were graded as clearance in this secondlevel categorization, to indicate that these infections were transient in nature ( ). The same was true for cases in category n p 36 2 if the incident infection cleared without persistence. Among the final category (6), we also picked up all cases fulfilling the above-defined criteria of type-specific or non-type-specific persistence, to be included as such in this secondary classification. This leaves only 9 cases in category 6 in the new classification. The exact durations (in months) of persistence for each individual case of persistent lesion ( ) were calculated. These n p 177 primary and secondary approaches were combined to define the persistent cases as type-specific and non-type-specific persistors. The individual genotypes responsible for either type-specific or non-type-specific persistence at each follow-up visit were recorded, and the same was done for individual HPV species, with use of the phylogenetic HPV classification [4] . Finally, we identified whether the species that persisted was, indeed, the same as that detected at the baseline visit or at the follow-up visit when the patient first had positive results for HPV. This enabled the computing of the species-specific (recorded at genotype level) persistence and its predictors.
Predictors of type-specific persistence analyzed by generalized estimating equation (GEE).
To analyze the predictors of genotype-specific HPV persistence, we used this species-specific persistence approach to avoid stratifying the cases into individual types with single or few cases only. Furthermore, we were only interested in persistence of the key high-risk HPV In this analysis, a GEE modeling was used, clustered by patient ID and run in univariate and multivariate mode [24, 25] . GEE adjusts for the serial correlation within subjects due to the longitudinal nature (follow-up visits) of the data by modeling the covariance structure within subjects. The dependent variable was binomial (persistence, yes vs no), and therefore, the logit link function was used. The independent working correlation structure with a robust variance estimator (for 95% confidence intervals) to account for within-subject correlation was selected as the best-fitted covariance pattern, with use of the quasi-likelihood information criterion [25] . Because HPV persistence depends on the time between the subsequent samples, a time variable (follow-up visit) was included as a covariate in these GEE models. In the univariate GEE models, we first tested all covariates recorded at baseline (including serological data) and previously implicated as potential risk factors of HPV infections in our cohort [12, 18] . In the final multivariate GEE model, only the variables that were significant in the univariate model were entered, adjusted for age (continuous variable recorded at each follow-up visit). All statistical tests performed were 2-sided and were declared to be significant at the P ! level. .05
RESULTS
Type-specific point prevalence. The type-specific point prevalence was evaluated in each follow-up visit separately as shown in Table 1 . At all time points, the single most frequent genotype was HPV16, followed by multiple-type infection.
At baseline, 16.3% ( ) of the women were HPV posn p 53 itive. The single most frequent genotype was HPV16 (20.8%; ), followed by HPV45 (5.7%; ), HPV43 (3.8%; n p 11 n p 3 ), HPV58 (3.8%;
), and HPV70 (3.8%; ). n p 2 n p 2 n p 2 Multiple-type infections included 45.3% ( ) of all HPVn p 24 positive cases, and HPV16 was detected in 83.3% ( ) of n p 20 multiple-type infections.
At the second visit (2 months), the total HPV prevalence remained practically unchanged at 15.1%, with HPV16 being the most common individual type (30.4%;
). Next in n p 14 frequency were HPV56 and HPV70, both with 8.7% prevalence ( ). The prevalence of multiple-type infections decreased n p 4 to 26.1% ( ). HPV16 was detected in 50% ( ) of n p 12 n p 6 multiple-type infections.
At the third visit (12 months), HPV prevalence increased substantially to 47.7% ( ). At this point, HPV16 repn p 137 resented 43.9% ( ) of the positive cases, and multiple n p 68 types were present in 32.1% ( ) of infections, with HPV16 n p 44 detected in 65.9% ( ). HPV prevalence further increased n p 29 at the 24-month visit to 57.2% (a 10% increase). Much of this increase was attributable to HPV16, which represented 43.9% ) at the expense of multiple-type n p 95 infections, which decreased to 21.3% ( ); HPV16 was n p 32 detected in 87.5% ( ) of multiple-type infections. Ben p 28 tween the 36-month and 6-year follow-up visits, there were women lost to follow-up, with somewhat decreased HPV prevalence (32.2%;
). Also at this 6-year visit, HPV16 was n p 55 the most dominant type, representing 63.3% ( ) of the n p 35 HPV-positive cases, followed by the multiple-type infections, with 23.6% ( ) prevalence; HPV16 was detected in 76.9% n p 13 ( ) of the multiple-type infections. n p 10
Of the HPV species detected, the most dominant at baseline was species 9, which included 28.3% ( ) of the cases. n p 15 The second most common species was number 7, which included 11.3% ( ) of the cases. The trend observed during n p 6 follow-up was the increase of species 9 and decrease of species 7, with the peak for species 9 reached at the 36-month visit (69.3%; ). n p 104 Time of viral persistence. The time of persistence was evaluated for the single genotypes and their respective species, as shown in Table 2 . Of the individual genotypes, the longest persistence time was recorded for HPV35 (38.7 months), but there was only a single case. This was followed by HPV58, with a mean persistence of 32.1 months (range, 12.0-88.8 months;
). For HPV16, which was the most common type, the n p 4 mean persistence was 23.9 months (range, 2.4-78.8 months;
). The duration of persistence for multiple-type infecn p 80 tions was close to that of HPV16 (mean, 20.9 months [range,
11.2-33.9 months];
). For all other high-risk and lown p 7 risk HPV types, the duration of persistence was much lower (eg, HPV6 mean persistence, 14.1 months [range, 12.2-15.5 months];
). n p 3 The duration of persistence of species 9 was significantly greater than all others (mean, 24.1 months [range, 2.4-88.8 months];
). The mean persistence of species 7 was 13.4 n p 90 months (range, 1.6-34.1 months). The other species had persistence durations of 12.4-19.1 months ( Table 2) .
Predictors of species-specific persistence. The predictors of species-specific persistence of HPV genotypes during the follow-up were analyzed for species 7 and 9 with use of GEE modeling (Table 3 ). In the univariate GEE model, the following 3 variables were significant predictors of species 7/9 HPV persistence: (1) early onset of sexual activity, (2) early initiation of oral contraceptive use, and (3) early onset of smoking. When all significant and borderline significant variables of the univariate GEE model were entered in the multivariate (adjusted) GEE model together with mother's age, the following 3 variables became independent predictors of the persistence of species 7/ 9 HPV infections: (1) age (persistence more common among older women), (2) oral sex (increased the risk of persistence; not practicing oral sex was protective with an odds ratio of 0.37), and (3) early onset of smoking (age reference, 10-13 years; odds ratio, 0.51 [95% confidence interval, 1.27-0.98];
). P p .046
DISCUSSION
The point prevalence and persistence of 24 different HPV genotypes were analyzed in the prospective Finnish Family HPV Study in a 6-year longitudinal setting, which makes this cohort unique. Most other studies [5, 12, [26] [27] [28] have only focused on a few high-risk HPV types and report short follow-up times (maximum follow-up, 24 months) [5, [26] [27] [28] [29] .
HPV16 was the most common HPV genotype at baseline and during the entire follow-up. This is in line with most of the other studies involving female genital HPV infections [12, 17, 27, 30] , In our cohort, HPV16 was followed in decreasing order of frequency by HPV types 6, 45, 43, 58, and 70. In a few studies, HPV58 has been reported to be the second-most prevalent genotype after HPV16 [6, 13, 27, 30, 31] . Worldwide, HPV58 is regarded as the third-most common type in Asia, but in Europe, its estimated prevalence is !1% [4] . HPV18, which is the second-most common type in Europe, was uncommon in our cohort. Interestingly, HPV70 was detected frequently at the second and third visits, with prevalences of 8.7% and 6.6%, respectively, closely matching the 5.7% prevalence in another recent report [31] . Of the HPV species, species 9 was the most common, followed by species 7, as reported elsewhere [13] .
The proportion of multiple-type HPV infection was high, second only to HPV16 in overall prevalence. Recently, multiple infections were shown to be more prevalent in a young Danish cohort (aged 20-29 years) [17] representing similar age coverage as in our cohort. This is in sharp contrast to menopausal women (aged 150 years), among whom single-type infections predominate and are frequently associated with high-grade cervical intraepithelial neoplasia [32] . It should be noted that all women in our cohort were pregnant at baseline, which might affect the type distribution.
There is no general consensus regarding the definition of persistent HPV infection, which complicates a direct comparison of different studies. We defined type-specific persistence as any woman with positive test results for the same HPV genotype in у2 subsequent samples during follow-up. In our cohort, HPV6 infections persisted 14.1 months, which is longer than reported (6.5 months) in a previous study with only 24 months of follow-up time [5] . In the present series, HPV35 showed the longest mean persistence (38.7 months, but there was only 1 case), followed by HPV58 (32.1 months), HPV16 (23.9 months), and multiple-type infections (20.9 months). Even though there were only 4 cases of HPV58 infection, these findings are in agreement with some recent reports, in which HPV16 and HPV58 were the 2 genotypes most likely to persist [12, 26, 27] . In other studies, HPV16 alone has been shown to persist longest [11, 12, 28] , with persistence ranging from 18.3 months [5] to 16.1 months [12] and 118 months [28] . The persistence duration of 23.9 months reported here is even longer, most likely because of the longer (6 years) follow-up time, compared with most of the recent studies. The persistence was longest for species 9 (24.1 months), as reported elsewhere [13] . This is not surprising, because all major high-risk HPV types belong to species 9.
We used species 7/9 genotype-specific persistence as an end point in our GEE models, because these are the clinically most important and globally most frequent HPV types. In the univariate GEE model, there was a significantly increased risk of species 7/9 infection to persist among those who had started sexual activity before the age of 13 years (Table 3 ). In fact, 7 mothers (2.4%) had their first sexual intercourse before the age of 13 years, and of those, 42.9% ( ) had a persistent typen p 3 specific infection by species 7/9 genotypes. This corroborates recent data indicating that high-risk HPV infection in women aged !15 years had an increased the risk of becoming persistent [26] . In our multivariate analysis, the early onset of sexual activity lost it statistical significance as independent predictor, which is in line with another study [6] . We suspect that early onset of sexual activity is a proxy of "high-risk" sexual behavior (ie, oral sex and smoking), and it is the latter that are the true predictors of high-risk HPV persistence as observed in multivariate GEE. Indeed, this was shown to be the case when the onset of sexual activity (cutoff, 16 years) was controlled for smoking and further stratified by oral sex in the Mantel-Haenszel test; a significant common odds ratio (odds ratio, 3.10 [95% confidence interval, 1.89-5.07];
) was obtained, P ! .001 indicating that these 3 variables are closely associated (data not shown).
Early onset of oral contraceptive use was another factor associated with an increased risk of HPV persistence, which is consistent with many other studies [26, 33] . In most studies, oral contraceptive use has been reported as years of use, and a duration of use 15 years has been associated with an increased risk of cervical cancer [34] . In our cohort, early initiation of oral contraceptive use was also closely correlated with the total time of oral contraceptive usage, the latter variable being omitted from the GEE model because of collinearity. How oral contraceptives increase the risk of HPV persistence is not clear. In a transgenic mouse model, however, a continuous (unopposed) estrogen exposure together with HPV16 E6/E7 expression induces the development of cervical cancer in all animals within 7-8 months [35] .
Smoking is a well established risk factor for cervical intraepithelial neoplasia and cervical cancer [16] . However, there are few studies assessing the role of smoking in type-specific HPV persistence. A cohort study from Canada concluded that women who smoked 1 or 2 packs of cigarettes per day for at least 1 year were only one-half as likely to clear their HPV infection as nonsmokers [36] . In our study, early initiation of smoking (aged, !13 years) was closely correlated with the total time (years) of being a smoker, implicating a dose/exposure relationship (data not shown), and was a significant predictor of type-specific persistence even in a multivariate model (Table  3) . Similar data were previously reported in our New Independent States Cohort, where being a current smoker was the only predictor of persistent infection, analyzed collectively for 13 high-risk HPV types with the HC2 assay [29] . It has been proposed that smoking adversely affects the host immunosurveillance system against viral infections [37] . Thus, women smokers aged !30 years have been shown to be less likely to either seroconvert or maintain HPV16/18 antibodies, compared with nonsmokers [38] . Initiation of smoking at a young age may interfere with the developing immunological system, thus contributing to its failure to eradicate viral infections. In addition, the mucosa, especially the transformation zone, might be more vulnerable at early age than later. More studies are needed to further elucidate this in the genital tract.
Oral sex was another independent predictive factor for typespecific persistence (Table 3) . Not unexpectedly, nonpractice of oral sex had a protective effect against type-specific persistence. It can be reasoned that a regular exposure of the genital tract to HPV from the oral mucosa might promote viral persistence. In our previous study, however, we failed correlate baseline high-risk HPV DNA status in the oral mucosa with the practice of oral sex [39] . On the basis of analysis in a longitudinal setting in the present study, oral sex could represent 1 of the potential mechanisms associated with spouse-to-spouse transmission of HPV, but this needs further assessment with more complex models (eg, multilevel mixed-effects models).
At baseline, all women were pregnant and in their third trimester. We found a clear 3-fold increase in HPV prevalence from the baseline to the 12-month visit. This corroborates our recent data from this cohort, where a clear association was disclosed between HPV carriage (point prevalence) and timing of 2 pregnancies (index pregnancy and second pregnancy) [40] . There was a significantly increased carriage of high-risk HPV in both cervical and oral mucosa during the interpregnancy period, compared with the second pregnancy or the index pregnancy. This suggests that hormonal or immunological factors during the postpartum period may be protective against HPV infections. The observed increase in HPV prevalence at the 12-month follow-up visit might be explained by a new exposure during this interpregnancy period, which is also supported also by the serological data from these women, indicating a clear peak between the baseline and the 12-month visits [41] .
Taken together, in this cohort of newly delivered mothers followed up for 6 years after their index pregnancy, HPV16 was the most frequent persisting HPV genotype, followed by multiple-type infections. Early initiation of smoking, practicing oral sex, and older age increase the risk for persistence of the species 7/9 HPV genotypes. These data might have important implications in adolescence and maternity counseling aimed at reducing the risks of persistent high-risk HPV infections.
